数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Andre Choulika Chairman and Director 52 27.30万美元 未持股 2017-07-19
Alain Godard Director 71 未披露 未持股 2017-07-19
Philippe Dumont Director 66 未披露 未持股 2017-07-19
Anna Ewa Kozicz Stankiewicz Director 42 未披露 未持股 2017-07-19
Laurent Arthaud Director 54 未披露 未持股 2017-07-19

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Joseph B. Saluri General Counsel, Executive Vice President - Corporate Development 50 未披露 未持股 2017-07-19
章峰 Chief Operations Officer 42 未披露 未持股 2017-07-19
Federico A. Tripodi Chief Executive Officer 40 61.68万美元 未持股 2017-07-19
Bryan W. J. Corkal Chief Financial Officer 49 1.93万美元 未持股 2017-07-19
Daniel Voytas Chief Science Officer 54 55.32万美元 未持股 2017-07-19
Manoj Sahoo Chief Commercial Officer 42 未披露 未持股 2017-07-19
Glenn Bowers Vice President of Breeding 64 未披露 未持股 2017-07-19
Michel Arbadji Director of Business Development 52 未披露 未持股 2017-07-19

董事简历

中英对照 |  中文 |  英文
Andre Choulika

Andre Choulika,他是Cellectis公司的创始人之一,并一直担任我们的董事会主席兼首席执行官(2000年以来)。他一直担任Calyxt公司的总裁(2010年8月以来)。从1997年到1999年,他曾担任Boston Children’s Hospital的分子医学部门的博士后研究员,在那里他曾担任用于修改复杂基因组的大范围核酸酶分析和使用先驱。他任职于几家生物技术公司的董事会。他持有the University of Paris VI Pierre et Marie Curie的分子生物学博士学位。此后,他获得哈佛医学院的遗传学系的研究奖学金。他也曾在the HEC (Challenge +)进行管理培训。


Andre Choulika is one of the founders of Cellectis and served as Chief Executive Officer since the Company’s inception in 1999. He served as Chairman of our board of directors from 2011 to November 2020 and Chairman of the board of directors of Calyxt from August 2010 to July 2020. He is CEO and Chairman of Cellectis, Inc. since December 2014 and Cellectis Biologics, Inc. since January 2019. From 1997 to 1999 Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI Pierre et Marie Curie, he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). Since June 2019 Dr. Choulika served at the board of directors of Institut Pasteur. André Choulika was recently awarded Chevalier of the Légion d’Honneur in France.
Andre Choulika,他是Cellectis公司的创始人之一,并一直担任我们的董事会主席兼首席执行官(2000年以来)。他一直担任Calyxt公司的总裁(2010年8月以来)。从1997年到1999年,他曾担任Boston Children’s Hospital的分子医学部门的博士后研究员,在那里他曾担任用于修改复杂基因组的大范围核酸酶分析和使用先驱。他任职于几家生物技术公司的董事会。他持有the University of Paris VI Pierre et Marie Curie的分子生物学博士学位。此后,他获得哈佛医学院的遗传学系的研究奖学金。他也曾在the HEC (Challenge +)进行管理培训。
Andre Choulika is one of the founders of Cellectis and served as Chief Executive Officer since the Company’s inception in 1999. He served as Chairman of our board of directors from 2011 to November 2020 and Chairman of the board of directors of Calyxt from August 2010 to July 2020. He is CEO and Chairman of Cellectis, Inc. since December 2014 and Cellectis Biologics, Inc. since January 2019. From 1997 to 1999 Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI Pierre et Marie Curie, he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). Since June 2019 Dr. Choulika served at the board of directors of Institut Pasteur. André Choulika was recently awarded Chevalier of the Légion d’Honneur in France.
Alain Godard

2007年10月以来Alain Godard 是我们董事会的一员。自2002年以来Godard先生一直担任植物生物技术和管理的顾问。他担任SARLGodard公司首席执行官。自2009年6月以来,他也担任Fermentalg SA的董事会。之前从1999年到2001年他担任Aventis Cropscience管理委员会主席同时任职于 Aventis Cropscience 执行委员会。自1975年加入公司他担任Rhne-Poulenc Agrochimie的几个高管职位,在1991年他成为该公司的首席执行官,在1995年担任董事长兼首席执行官。1997年Godard先生被任命为Rhne-Poulenc Agrochimie集团执行委员会,他负责监管动植物健康领域的运营和亚洲地区。1999年,在Hoechst和Rhne-Poulenc合并中,他表现活跃并最终促进了Aventis的成立。Godard先生毕业于 图卢兹cole Nationale Suprieure Agronomique。在1967年作为一个研究员,他在非洲的Institut de Recherche pour les Huiles et Olagineux研究所开始了他的农学生涯,负责研究油和油质的植物。


Alain Godard has served as a member of Cellectis’ board of directors since 2007. Since March 2020 he served as director of Cineart, a cultural organization. From July 2017 to May 2019 Mr. Godard served at the board of directors of Calyxt. He joined the French chemical group Rhône-Poulenc in 1975 where he held various management positions in France and abroad before becoming CEO of the agrochemical subsidiary in 1991. In 1999 he was directly involved in the merger of Rhône-Poulenc and Hoechst to create Aventis and was appointed CEO of the Aventis CropScience subsidiary with a significant involvement in seeds and agricultural biotechnology. He left Aventis in 2002 to create a consulting company, SARL Godard & Co., specialized in agriculture and biotechnology, where he has served as Chief Executive Officer since 2009. Until 2016 Mr. Godard also served on the board of directors of Fermentalg S.A. He is a graduate of the Ecole Nationale Supérieure Agronomique de Toulouse and began his agronomy career in 1967 in Africa as a researcher at the Institut de Recherche pour les Huiles et Oléagineux.
2007年10月以来Alain Godard 是我们董事会的一员。自2002年以来Godard先生一直担任植物生物技术和管理的顾问。他担任SARLGodard公司首席执行官。自2009年6月以来,他也担任Fermentalg SA的董事会。之前从1999年到2001年他担任Aventis Cropscience管理委员会主席同时任职于 Aventis Cropscience 执行委员会。自1975年加入公司他担任Rhne-Poulenc Agrochimie的几个高管职位,在1991年他成为该公司的首席执行官,在1995年担任董事长兼首席执行官。1997年Godard先生被任命为Rhne-Poulenc Agrochimie集团执行委员会,他负责监管动植物健康领域的运营和亚洲地区。1999年,在Hoechst和Rhne-Poulenc合并中,他表现活跃并最终促进了Aventis的成立。Godard先生毕业于 图卢兹cole Nationale Suprieure Agronomique。在1967年作为一个研究员,他在非洲的Institut de Recherche pour les Huiles et Olagineux研究所开始了他的农学生涯,负责研究油和油质的植物。
Alain Godard has served as a member of Cellectis’ board of directors since 2007. Since March 2020 he served as director of Cineart, a cultural organization. From July 2017 to May 2019 Mr. Godard served at the board of directors of Calyxt. He joined the French chemical group Rhône-Poulenc in 1975 where he held various management positions in France and abroad before becoming CEO of the agrochemical subsidiary in 1991. In 1999 he was directly involved in the merger of Rhône-Poulenc and Hoechst to create Aventis and was appointed CEO of the Aventis CropScience subsidiary with a significant involvement in seeds and agricultural biotechnology. He left Aventis in 2002 to create a consulting company, SARL Godard & Co., specialized in agriculture and biotechnology, where he has served as Chief Executive Officer since 2009. Until 2016 Mr. Godard also served on the board of directors of Fermentalg S.A. He is a graduate of the Ecole Nationale Supérieure Agronomique de Toulouse and began his agronomy career in 1967 in Africa as a researcher at the Institut de Recherche pour les Huiles et Oléagineux.
Philippe Dumont

Philippe Dumont自2017年7月以来一直担任我们的董事会成员。Dumont先生于2012年12月从Bayer Cropscience退休,自2002年5月以来一直受雇于该公司。在拜耳,他担任种子技术管理主管,并负责监督全球监管事务和监管科学职能,管理,公共和政府事务以及影响转基因生物和种子的沟通。直到2006年,Dumont先生还监督种子业务的法律和知识产权职能。从1998年12月到2002年4月,Dumont先生还在Aventis Crop Science担任相同的职务。1987年至1998年,Dumont先生担任RHô;NE-Poulenc Agrochimie的总法律顾问。在1987年搬到法国之前,Philippe曾在Cravath Swaine&Moore担任合伙人,1975年至1981年在海湾石油公司担任国际法律顾问(1981年至1983年),并于1983年至1986年在华盛顿特区担任独立执业律师。Philippe从纽约和哥伦比亚特区的律师事务所退休,毕业于乔治敦大学法律中心(1975年法学博士)和哥伦比亚大学(1972年以优异成绩获得学士学位)。自2013年6月以来,他一直担任法国生物技术协会(Association Fran&231;Aise des Biotechnologies V&233;G&233;Tales)的董事,负责国际关系,在那里他试图促进公众和政府对新育种技术和相关监管问题的了解。


Philippe Dumont has served as a member of our Board of Directors since July 2017. Mr. Dumont retired in December 2012 from Bayer CropScience, where he was employed since May 2002. At Bayer he held the position of Head of Technology Management, Seeds, and was responsible for supervising globally the Regulatory Affairs and Regulatory Science functions, Stewardship, Public and Governmental Affairs and Communication impacting GMOs and seeds. Until 2006 Mr. Dumont also supervised the Legal and Intellectual Property functions in the seed business. Mr. Dumont also held the same responsibilities at Aventis Crop Science from December 1998 until April 2002. From 1987 to 1998 Mr. Dumont was General Counsel of Rhône-Poulenc Agrochimie. Prior to moving to France in 1987 Philippe held positions as an associate at Cravath Swaine & Moore 1975 - 1981 international legal counsel at Gulf Oil Corporation (1981-1983) and as solo practitioner in Washington D.C. from 1983 - 1986. Philippe is retired from the New York and District of Columbia Bars and is a graduate of the Georgetown University Law Center (JD 1975) and Columbia University (BA, magna cum laude 1972). Since June 2013 he has been serving as a director of Association Française des Biotechnologies Végétales, responsible for international relations, where he tries to promote public and governmental understanding of new breeding techniques and related regulatory issues.
Philippe Dumont自2017年7月以来一直担任我们的董事会成员。Dumont先生于2012年12月从Bayer Cropscience退休,自2002年5月以来一直受雇于该公司。在拜耳,他担任种子技术管理主管,并负责监督全球监管事务和监管科学职能,管理,公共和政府事务以及影响转基因生物和种子的沟通。直到2006年,Dumont先生还监督种子业务的法律和知识产权职能。从1998年12月到2002年4月,Dumont先生还在Aventis Crop Science担任相同的职务。1987年至1998年,Dumont先生担任RHô;NE-Poulenc Agrochimie的总法律顾问。在1987年搬到法国之前,Philippe曾在Cravath Swaine&Moore担任合伙人,1975年至1981年在海湾石油公司担任国际法律顾问(1981年至1983年),并于1983年至1986年在华盛顿特区担任独立执业律师。Philippe从纽约和哥伦比亚特区的律师事务所退休,毕业于乔治敦大学法律中心(1975年法学博士)和哥伦比亚大学(1972年以优异成绩获得学士学位)。自2013年6月以来,他一直担任法国生物技术协会(Association Fran&231;Aise des Biotechnologies V&233;G&233;Tales)的董事,负责国际关系,在那里他试图促进公众和政府对新育种技术和相关监管问题的了解。
Philippe Dumont has served as a member of our Board of Directors since July 2017. Mr. Dumont retired in December 2012 from Bayer CropScience, where he was employed since May 2002. At Bayer he held the position of Head of Technology Management, Seeds, and was responsible for supervising globally the Regulatory Affairs and Regulatory Science functions, Stewardship, Public and Governmental Affairs and Communication impacting GMOs and seeds. Until 2006 Mr. Dumont also supervised the Legal and Intellectual Property functions in the seed business. Mr. Dumont also held the same responsibilities at Aventis Crop Science from December 1998 until April 2002. From 1987 to 1998 Mr. Dumont was General Counsel of Rhône-Poulenc Agrochimie. Prior to moving to France in 1987 Philippe held positions as an associate at Cravath Swaine & Moore 1975 - 1981 international legal counsel at Gulf Oil Corporation (1981-1983) and as solo practitioner in Washington D.C. from 1983 - 1986. Philippe is retired from the New York and District of Columbia Bars and is a graduate of the Georgetown University Law Center (JD 1975) and Columbia University (BA, magna cum laude 1972). Since June 2013 he has been serving as a director of Association Française des Biotechnologies Végétales, responsible for international relations, where he tries to promote public and governmental understanding of new breeding techniques and related regulatory issues.
Anna Ewa Kozicz Stankiewicz

Anna Ewa Kozicz Stankiewicz自2017年7月起担任我们的董事会成员。Kozicz女士获得了哥伦比亚学院的数学和经济学学士学位以及哥伦比亚商学院的MBA学位。她于1996年在瑞士信贷第一波士顿(Credit Suisse First Boston)的金融机构集团开始了她的职业生涯,然后于2000年搬到高盛(Goldman Sachs),在那里她担任过多个职位,包括董事总经理,并将大部分时间用于主要战略集团,专注于全球农业部门。她于2009年搬到Caxton Associates,担任股票投资组合经理,然后于2012年搬到BlackRock,在那里她曾担任美国战略和企业发展主管以及私人资产投资组合经理。在贝莱德(BlackRock)任职期间,她曾担任总部位于纽约的联邦信用合作社PSFCU的董事会董事。她于2017年离开贝莱德,创建了一个新的投资平台Anthelion Capital,专注于农业,能源和运输服务的可持续性。


Anna Ewa Kozicz Stankiewicz has served as a member of our Board of Directors since July 2017. Mrs. Kozicz received a BA in Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio Manager before moving to BlackRock in 2012 where she worked as Head of US Strategy and Corporate Development as well as a private assets Portfolio Manager. During her time at BlackRock, she served as a director on the board of a New York-based federal credit union PSFCU. She left BlackRock in 2017 to start a new investment platform, Anthelion Capital, focused on sustainability in agriculture, energy and transportation services.
Anna Ewa Kozicz Stankiewicz自2017年7月起担任我们的董事会成员。Kozicz女士获得了哥伦比亚学院的数学和经济学学士学位以及哥伦比亚商学院的MBA学位。她于1996年在瑞士信贷第一波士顿(Credit Suisse First Boston)的金融机构集团开始了她的职业生涯,然后于2000年搬到高盛(Goldman Sachs),在那里她担任过多个职位,包括董事总经理,并将大部分时间用于主要战略集团,专注于全球农业部门。她于2009年搬到Caxton Associates,担任股票投资组合经理,然后于2012年搬到BlackRock,在那里她曾担任美国战略和企业发展主管以及私人资产投资组合经理。在贝莱德(BlackRock)任职期间,她曾担任总部位于纽约的联邦信用合作社PSFCU的董事会董事。她于2017年离开贝莱德,创建了一个新的投资平台Anthelion Capital,专注于农业,能源和运输服务的可持续性。
Anna Ewa Kozicz Stankiewicz has served as a member of our Board of Directors since July 2017. Mrs. Kozicz received a BA in Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio Manager before moving to BlackRock in 2012 where she worked as Head of US Strategy and Corporate Development as well as a private assets Portfolio Manager. During her time at BlackRock, she served as a director on the board of a New York-based federal credit union PSFCU. She left BlackRock in 2017 to start a new investment platform, Anthelion Capital, focused on sustainability in agriculture, energy and transportation services.
Laurent Arthaud

Laurent Arthaud,2007年4月以来,他成为我们董事会的成员。2006年以来,他担任Bpifrance Investissement(原CDC Entreprises,巴黎的在生物技术领域的投资的私人股本公司)的总合伙人。从2004年到2006年,他曾是Pharmavent Partners(总部在巴黎)的管理合伙人。从1999年到2004年,他管理 Aventis的风险投资活动和管理风险资本基金 F.C.P.R.Genavent。他的事业始于1986年在法国国家统计局(INSEE)然后是the Forecasts Department of the French Ministry of Finances。1995年他加入法国总理 Alain Juppéas的技术顾问内阁管理劳动力和失业问题。他于1997年加入Rhne-Poulenc部门并担任科学委员会秘书长。他是巴里理工学院(the Ecole Polytechnique of Paris)和 Ecole Nationale de la Statistique et de l’Administration Economique的毕业生。


Laurent Arthaud has served as a member of our board of directors since October 28 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement formerly CDC Enterprises, a subsidiary of Caisse des Dépôts since 2012. He currently serves on the boards of directors of Kurma Life Sciences Partners, Adocia, Sparingvision, Aledia and Ribogenics, Inc. and Enyo Pharma. Since July 2020 Mr. Arthaud served at the board of directors of Calyxt, representing Cellectis. He previously served at the Calyxt’s board of directors from July 2017 to May 2019. He served on the board of directors of TxCell from 2012 to 2018 on the board of directors of Emertee Gestion from 2006 to 2016 and on the board of directors of Scynexis, Inc. from 200 to 2015. From 2006 to 2012 Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Since 2009 Mr. Arthaud has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the École Polytechnique and the École Nationale de Statistique et d’Administration Économique.
Laurent Arthaud,2007年4月以来,他成为我们董事会的成员。2006年以来,他担任Bpifrance Investissement(原CDC Entreprises,巴黎的在生物技术领域的投资的私人股本公司)的总合伙人。从2004年到2006年,他曾是Pharmavent Partners(总部在巴黎)的管理合伙人。从1999年到2004年,他管理 Aventis的风险投资活动和管理风险资本基金 F.C.P.R.Genavent。他的事业始于1986年在法国国家统计局(INSEE)然后是the Forecasts Department of the French Ministry of Finances。1995年他加入法国总理 Alain Juppéas的技术顾问内阁管理劳动力和失业问题。他于1997年加入Rhne-Poulenc部门并担任科学委员会秘书长。他是巴里理工学院(the Ecole Polytechnique of Paris)和 Ecole Nationale de la Statistique et de l’Administration Economique的毕业生。
Laurent Arthaud has served as a member of our board of directors since October 28 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement formerly CDC Enterprises, a subsidiary of Caisse des Dépôts since 2012. He currently serves on the boards of directors of Kurma Life Sciences Partners, Adocia, Sparingvision, Aledia and Ribogenics, Inc. and Enyo Pharma. Since July 2020 Mr. Arthaud served at the board of directors of Calyxt, representing Cellectis. He previously served at the Calyxt’s board of directors from July 2017 to May 2019. He served on the board of directors of TxCell from 2012 to 2018 on the board of directors of Emertee Gestion from 2006 to 2016 and on the board of directors of Scynexis, Inc. from 200 to 2015. From 2006 to 2012 Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Since 2009 Mr. Arthaud has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the École Polytechnique and the École Nationale de Statistique et d’Administration Économique.

高管简历

中英对照 |  中文 |  英文
Joseph B. Saluri

Joseph B. Saluri,他一直担任Zevra Therapeutics, Inc.的董事。公司成立于2014年1月。自2018年8月以来,Saluri先生一直担任BlueAllele, LLC(位于明尼苏达州奥克代尔的初创生物技术公司)的首席执行官兼董事会主席。2017年6月至2018年3月,他曾担任Calyxt, Inc.的总法律顾问兼执行副总裁。在加入Calyxt, Inc.之前,他曾担任Stine Seed Company及其附属公司的总法律顾问(1999年7月至2017年3月)。1993年6月至1999年6月,他在爱荷华州得梅因和英国伦敦的Nicholas Critelli Associates, PC担任律师和律师。2010年5月至2017年7月,他担任Newlink Genetics Corporation(一家上市生物制药公司)的董事。他持有Drake University Law School的法学博士学位,Drake University Law School的工商管理学士学位,Drake University的工商管理学士学位。


Joseph B. Saluri,has served as a director of Zevra Therapeutics, Inc. Company since January 2014. Since August 2018, Mr. Saluri has served as the chief executive officer and chairman of the board of BlueAllele, LLC, a start-up biotechnology company located in Oakdale, Minnesota. Mr. Saluri previously served as general counsel and executive vice president for Calyxt, Inc. from June 2017 to March 2018. Prior to his employment with Calyxt, Inc., Mr. Saluri served as general counsel for Stine Seed Company and its affiliates from July 1999 to March 2017. Mr. Saluri practiced as an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines, Iowa and London, England from June 1993 to June 1999. Mr. Saluri served as a director of Newlink Genetics Corporation, a public biopharmaceutical company from May 2010 to July 2017. Mr. Saluri received his J.D. degree from Drake University Law School and his B.S.B.A. degree from Drake University Law School and his B.S.B.A. degree from Drake University.
Joseph B. Saluri,他一直担任Zevra Therapeutics, Inc.的董事。公司成立于2014年1月。自2018年8月以来,Saluri先生一直担任BlueAllele, LLC(位于明尼苏达州奥克代尔的初创生物技术公司)的首席执行官兼董事会主席。2017年6月至2018年3月,他曾担任Calyxt, Inc.的总法律顾问兼执行副总裁。在加入Calyxt, Inc.之前,他曾担任Stine Seed Company及其附属公司的总法律顾问(1999年7月至2017年3月)。1993年6月至1999年6月,他在爱荷华州得梅因和英国伦敦的Nicholas Critelli Associates, PC担任律师和律师。2010年5月至2017年7月,他担任Newlink Genetics Corporation(一家上市生物制药公司)的董事。他持有Drake University Law School的法学博士学位,Drake University Law School的工商管理学士学位,Drake University的工商管理学士学位。
Joseph B. Saluri,has served as a director of Zevra Therapeutics, Inc. Company since January 2014. Since August 2018, Mr. Saluri has served as the chief executive officer and chairman of the board of BlueAllele, LLC, a start-up biotechnology company located in Oakdale, Minnesota. Mr. Saluri previously served as general counsel and executive vice president for Calyxt, Inc. from June 2017 to March 2018. Prior to his employment with Calyxt, Inc., Mr. Saluri served as general counsel for Stine Seed Company and its affiliates from July 1999 to March 2017. Mr. Saluri practiced as an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines, Iowa and London, England from June 1993 to June 1999. Mr. Saluri served as a director of Newlink Genetics Corporation, a public biopharmaceutical company from May 2010 to July 2017. Mr. Saluri received his J.D. degree from Drake University Law School and his B.S.B.A. degree from Drake University Law School and his B.S.B.A. degree from Drake University.
章峰

章峰,本科毕业于清华大学计算机系,后获得杜克大学MBA学位。曾担任美国第一资本银行(Capital One)高级总监,是当时第一资本银行最资深的华人风险决策管理人员,唯一一名被任命为执行风险信用官的华人。在第一资本银行12年期间,章峰在零售信贷领域市场营销,产品设计和风险控制方面积累了丰富的经验,作为部门负责人独立管理100亿美元业务。同时,章峰还是第一资本银行数百名华人员工社团领导,在当地华人社区有着广泛的影响力。


Feng Zhang has been serving as Finvolution Group's chief executive officer since March 2020. Mr. Zhang also served as Finvolution Group's co-chief executive officer from September 2018 to March 2020 chief operating officer from July 2017 to September 2018 and chief risk officer from April 2015 to July 2017. Prior to joining Finvolution Group, Mr. Zhang held various positions including analyst, senior analyst, manager, senior manager, head of yield management, and senior director at Capital One Financial Services, a diversified bank that offers a broad array of financial products and services, from 2003 to 2015. Mr. Zhang received his bachelor's degree in computer science from Tsinghua University, master's degree in computer science from Chinese Academy of Science, master's degree in computer science from Virginia Tech, and MBA degree from Duke University, The Fuqua School of Business.
章峰,本科毕业于清华大学计算机系,后获得杜克大学MBA学位。曾担任美国第一资本银行(Capital One)高级总监,是当时第一资本银行最资深的华人风险决策管理人员,唯一一名被任命为执行风险信用官的华人。在第一资本银行12年期间,章峰在零售信贷领域市场营销,产品设计和风险控制方面积累了丰富的经验,作为部门负责人独立管理100亿美元业务。同时,章峰还是第一资本银行数百名华人员工社团领导,在当地华人社区有着广泛的影响力。
Feng Zhang has been serving as Finvolution Group's chief executive officer since March 2020. Mr. Zhang also served as Finvolution Group's co-chief executive officer from September 2018 to March 2020 chief operating officer from July 2017 to September 2018 and chief risk officer from April 2015 to July 2017. Prior to joining Finvolution Group, Mr. Zhang held various positions including analyst, senior analyst, manager, senior manager, head of yield management, and senior director at Capital One Financial Services, a diversified bank that offers a broad array of financial products and services, from 2003 to 2015. Mr. Zhang received his bachelor's degree in computer science from Tsinghua University, master's degree in computer science from Chinese Academy of Science, master's degree in computer science from Virginia Tech, and MBA degree from Duke University, The Fuqua School of Business.
Federico A. Tripodi

Federico A.Tripodi自2016年5月起担任我们的首席执行官。他持有Washington University’;S Olin Business School的工商管理硕士学位,以及Buenos Aires University的农艺工程学位,并在农业生物技术和种子行业的近20年职业生涯中积累了农业研发和产品开发的丰富经验。在加入Calyxt之前,Tripodi先生在巴西的孟山都公司’;s甘蔗部门担任了近三年的总经理。他曾在密苏里州圣路易斯的孟山都公司担任其他职务,包括公司战略2011-2013年Omega-3计划负责人(2009-2011年),油籽全球质量管理负责人(2008-2009年),以及多个其他职务,涉及管理技术组织的多学科研究团队(2001年至2008年)。在孟山都任职期间,Tripodi先生领导或参与了美洲各地的早期发现和后期商业化阶段产品发布,其中包括生物技术消费者特征(改良的大豆油组成)和农民特征(高产,耐旱,昆虫保护和除草剂耐受性)。Tripodi先生于1998年在阿根廷开始他的职业生涯,从事生物技术特征和化学制剂的现场研究,直到2001年搬到圣路易斯。Tripodi先生还拥有担任初创公司董事的经验,并以非盈利为目的在董事会任职。


Federico A. Tripodi has served as our Chief Executive Officer since May 2016. He holds a Master of Business Administration degree from Washington University’s Olin Business School, as well as an agronomic engineering degree from Buenos Aires University, and has gathered extensive experience in agricultural R&D and product development during his nearly two-decade career in the agriculture biotechnology and seeds industry. Prior to joining Calyxt, Mr. Tripodi worked as General Manager for Monsanto Company’s Sugarcane Division in Brazil for nearly three years. He held other roles for Monsanto in Saint Louis, Missouri, spanning Corporate Strategy 2011- 2013 Omega-3 Program Lead (2009 - 2011), Oilseeds Global Quality Management Lead (2008 - 2009) and multiple other roles that involved managing multidisciplinary research teams in the technology organization between 2001 and 2008. During his tenure at Monsanto, Mr. Tripodi led or participated with early discovery and late commercialization phase product launches across the Americas, which included biotech consumer traits (improved composition soybean oils) and farmer traits (high yield, drought tolerance, insect protection and herbicide tolerance). Mr. Tripodi started his career in Argentina in 1998 in field research of biotechnology traits and chemistry formulations until he moved to Saint Louis in 2001. Mr. Tripodi also has experience as a director of a startup and served on the board of directors for a not-for profit.
Federico A.Tripodi自2016年5月起担任我们的首席执行官。他持有Washington University’;S Olin Business School的工商管理硕士学位,以及Buenos Aires University的农艺工程学位,并在农业生物技术和种子行业的近20年职业生涯中积累了农业研发和产品开发的丰富经验。在加入Calyxt之前,Tripodi先生在巴西的孟山都公司’;s甘蔗部门担任了近三年的总经理。他曾在密苏里州圣路易斯的孟山都公司担任其他职务,包括公司战略2011-2013年Omega-3计划负责人(2009-2011年),油籽全球质量管理负责人(2008-2009年),以及多个其他职务,涉及管理技术组织的多学科研究团队(2001年至2008年)。在孟山都任职期间,Tripodi先生领导或参与了美洲各地的早期发现和后期商业化阶段产品发布,其中包括生物技术消费者特征(改良的大豆油组成)和农民特征(高产,耐旱,昆虫保护和除草剂耐受性)。Tripodi先生于1998年在阿根廷开始他的职业生涯,从事生物技术特征和化学制剂的现场研究,直到2001年搬到圣路易斯。Tripodi先生还拥有担任初创公司董事的经验,并以非盈利为目的在董事会任职。
Federico A. Tripodi has served as our Chief Executive Officer since May 2016. He holds a Master of Business Administration degree from Washington University’s Olin Business School, as well as an agronomic engineering degree from Buenos Aires University, and has gathered extensive experience in agricultural R&D and product development during his nearly two-decade career in the agriculture biotechnology and seeds industry. Prior to joining Calyxt, Mr. Tripodi worked as General Manager for Monsanto Company’s Sugarcane Division in Brazil for nearly three years. He held other roles for Monsanto in Saint Louis, Missouri, spanning Corporate Strategy 2011- 2013 Omega-3 Program Lead (2009 - 2011), Oilseeds Global Quality Management Lead (2008 - 2009) and multiple other roles that involved managing multidisciplinary research teams in the technology organization between 2001 and 2008. During his tenure at Monsanto, Mr. Tripodi led or participated with early discovery and late commercialization phase product launches across the Americas, which included biotech consumer traits (improved composition soybean oils) and farmer traits (high yield, drought tolerance, insect protection and herbicide tolerance). Mr. Tripodi started his career in Argentina in 1998 in field research of biotechnology traits and chemistry formulations until he moved to Saint Louis in 2001. Mr. Tripodi also has experience as a director of a startup and served on the board of directors for a not-for profit.
Bryan W. J. Corkal

Bryan W.J.Corkal自2016年12月起担任公司首席财务官。Corkal先生拥有加拿大多伦多约克大学的MBA学位和理学学士学位。马尼托巴大学土木工程专业。Corkal先生是CFA宪章持有人,并且是密苏里州的注册会计师。Corkal先生在种子和性状农业领域拥有丰富的财务和商业经验,在孟山都工作了17年以上,担任过各种财务和战略职务,包括收购和整合多家公司。在加入Calyxt之前,Corkal先生是Monsanto的北美供应链金融主管,该业务的年产品总成本超过20亿美元。Corkal先生在孟山都的职业生涯还包括担任拉丁美洲北部地区的投资者关系总监和财务区域首席财务官,该地区覆盖整个美洲的30个国家,他在该地区管理控制权,信贷和收款,税收,工资,金库,养老金计划和财务规划和分析功能。在他的职业生涯早期,Corkal先生曾在安永会计师事务所(Ernst&Young)和德尔坎公司(Delcan Corporation)担任加拿大和拉丁美洲多个项目的顾问。


Bryan W. J. Corkal has served as our Chief Financial Officer since December 2016. Mr. Corkal received his MBA from York University in Toronto, Canada and a B.Sc. in Civil Engineering from the University of Manitoba. Mr. Corkal is a CFA charter holder and is a CPA in the state of Missouri. Prior to joining Calyxt, Mr. Corkal was the North America Supply Chain Finance Lead at Monsanto, a business with a total annual product cost of over $2 billion. Mr. Corkal's career at Monsanto also included roles as Director of Investor Relations and Director of Finance regional CFO for the Latin America North division, a region covering 30 countries throughout the Americas, where he managed the controllership, credit and collections, tax, payroll, treasury, pension plan and financial planning and analysis functions. Early in his career, Mr. Corkal worked for Ernst & Young and Delcan Corporation as a consultant on a number of projects throughout Canada and Latin America.
Bryan W.J.Corkal自2016年12月起担任公司首席财务官。Corkal先生拥有加拿大多伦多约克大学的MBA学位和理学学士学位。马尼托巴大学土木工程专业。Corkal先生是CFA宪章持有人,并且是密苏里州的注册会计师。Corkal先生在种子和性状农业领域拥有丰富的财务和商业经验,在孟山都工作了17年以上,担任过各种财务和战略职务,包括收购和整合多家公司。在加入Calyxt之前,Corkal先生是Monsanto的北美供应链金融主管,该业务的年产品总成本超过20亿美元。Corkal先生在孟山都的职业生涯还包括担任拉丁美洲北部地区的投资者关系总监和财务区域首席财务官,该地区覆盖整个美洲的30个国家,他在该地区管理控制权,信贷和收款,税收,工资,金库,养老金计划和财务规划和分析功能。在他的职业生涯早期,Corkal先生曾在安永会计师事务所(Ernst&Young)和德尔坎公司(Delcan Corporation)担任加拿大和拉丁美洲多个项目的顾问。
Bryan W. J. Corkal has served as our Chief Financial Officer since December 2016. Mr. Corkal received his MBA from York University in Toronto, Canada and a B.Sc. in Civil Engineering from the University of Manitoba. Mr. Corkal is a CFA charter holder and is a CPA in the state of Missouri. Prior to joining Calyxt, Mr. Corkal was the North America Supply Chain Finance Lead at Monsanto, a business with a total annual product cost of over $2 billion. Mr. Corkal's career at Monsanto also included roles as Director of Investor Relations and Director of Finance regional CFO for the Latin America North division, a region covering 30 countries throughout the Americas, where he managed the controllership, credit and collections, tax, payroll, treasury, pension plan and financial planning and analysis functions. Early in his career, Mr. Corkal worked for Ernst & Young and Delcan Corporation as a consultant on a number of projects throughout Canada and Latin America.
Daniel Voytas

Daniel Voytas自2010年5月起担任我们的首席科学官。Voytas博士于1984年以优异成绩毕业于哈佛学院,并于1990年获得哈佛医学院遗传学博士学位。他是我们的联合创始人之一,也是Talen技术的发明人之一。他继续优化Talen在植物基因组靶向修饰中的用途。除了在Calyxt任职外,Voytas博士还是明尼苏达大学UMN遗传学,细胞生物学和发展部的教授,他于2008年加入该大学,并担任UMN&8217;S基因组工程中心主任。1992年,Voytas博士加入爱荷华州立大学。在此之前,他在约翰霍普金斯大学医学院进行博士后研究。Voytas博士是美国科学促进会的当选会员。


Daniel Voytas has served as our Chief Science Officer since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota UMN, which he joined in 2008 and Director of the UMN’s Center for Genome Engineering. In 1992 Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science.
Daniel Voytas自2010年5月起担任我们的首席科学官。Voytas博士于1984年以优异成绩毕业于哈佛学院,并于1990年获得哈佛医学院遗传学博士学位。他是我们的联合创始人之一,也是Talen技术的发明人之一。他继续优化Talen在植物基因组靶向修饰中的用途。除了在Calyxt任职外,Voytas博士还是明尼苏达大学UMN遗传学,细胞生物学和发展部的教授,他于2008年加入该大学,并担任UMN&8217;S基因组工程中心主任。1992年,Voytas博士加入爱荷华州立大学。在此之前,他在约翰霍普金斯大学医学院进行博士后研究。Voytas博士是美国科学促进会的当选会员。
Daniel Voytas has served as our Chief Science Officer since May 2010. Dr. Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our co-founders and one of the inventors of the TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr. Voytas is a professor in the Department of Genetics, Cell Biology and Development at the University of Minnesota UMN, which he joined in 2008 and Director of the UMN’s Center for Genome Engineering. In 1992 Dr. Voytas joined the faculty at Iowa State University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr. Voytas is an elected Fellow of the American Association for the Advancement of Science.
Manoj Sahoo

Manoj Sahoo自2017年3月起担任我们的首席商务官。他拥有达特茅斯学院塔克商学院的MBA学位和印度国家理工学院的化学工程学士学位。Sahoo先生拥有20多年的经验,在农业,食品,能源和材料领域的全球公司担任过各种职务,包括商业,战略,业务发展以及并购。加入我们之前,他曾担任Cargill公司的负责食品配料和生物工业企业的助理副总裁。在嘉吉,他负责超过10亿美元的收入,领导商业企业团队将生物基产品的收入增加了三倍,并管理与大型机构客户的关系。他曾在嘉吉(Cargill)任职,包括淀粉和甜味剂北美业务开发总监,以及新兴业务加速器(Emerging Business Accelerator)的投资团队成员,新兴业务加速器是一个由企业风险投资集团组建的集团,投资嘉吉的空白空间机会;他还曾在企业战略与发展集团工作。Sahoo先生还曾作为嘉吉的代表在Calysta Inc.和Rivertop Renewables的董事会任职。他负责领导嘉吉(Cargill)在工业生物技术领域的股权投资,包括与机构金融投资者共同投资实物资产,以建设6亿美元的商业规模水产养殖营养厂。他还担任LARTA Institute的行业咨询委员会成员,该委员会协助USDA,NIH和NSF进行商业化援助计划。


Manoj Sahoo has served as our Chief Commercial Officer since March 2017. He holds a MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemical Engineering from the National Institute of Technology in India. Mr. Sahoo has more than two decades of experience working in a variety of roles covering commercial, strategy, business development and mergers and acquisitions for global corporations in agriculture, food, energy and materials fields. Prior to joining us he was Assistant Vice President for Food Ingredients and Bio-industrial Enterprise at Cargill. At Cargill, he was responsible for revenues of over $1 billion, leading the commercial enterprise team to triple its earnings from bio-based products and managing relationships with large institutional customers. His prior roles at Cargill included Business Development Director for Starches and Sweeteners North America as well as serving as an investment team member with the Emerging Business Accelerator, a group structured along corporate venture capital groups, to invest in white space opportunities for Cargill; he also worked in the Corporate Strategy & Development Group. Mr. Sahoo has also served on the boards of both Calysta Inc. and Rivertop Renewables as a Cargill representative. He was responsible for leading Cargill’s equity investments in the industrial biotechnology space including co-investment in real assets with institutional financial investors to build a $600 million commercial-scale aquaculture nutrition plant. He also serves on Industry Advisory Board of Larta Institute which assists the USDA, NIH and NSF with the commercialization assistance program.
Manoj Sahoo自2017年3月起担任我们的首席商务官。他拥有达特茅斯学院塔克商学院的MBA学位和印度国家理工学院的化学工程学士学位。Sahoo先生拥有20多年的经验,在农业,食品,能源和材料领域的全球公司担任过各种职务,包括商业,战略,业务发展以及并购。加入我们之前,他曾担任Cargill公司的负责食品配料和生物工业企业的助理副总裁。在嘉吉,他负责超过10亿美元的收入,领导商业企业团队将生物基产品的收入增加了三倍,并管理与大型机构客户的关系。他曾在嘉吉(Cargill)任职,包括淀粉和甜味剂北美业务开发总监,以及新兴业务加速器(Emerging Business Accelerator)的投资团队成员,新兴业务加速器是一个由企业风险投资集团组建的集团,投资嘉吉的空白空间机会;他还曾在企业战略与发展集团工作。Sahoo先生还曾作为嘉吉的代表在Calysta Inc.和Rivertop Renewables的董事会任职。他负责领导嘉吉(Cargill)在工业生物技术领域的股权投资,包括与机构金融投资者共同投资实物资产,以建设6亿美元的商业规模水产养殖营养厂。他还担任LARTA Institute的行业咨询委员会成员,该委员会协助USDA,NIH和NSF进行商业化援助计划。
Manoj Sahoo has served as our Chief Commercial Officer since March 2017. He holds a MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemical Engineering from the National Institute of Technology in India. Mr. Sahoo has more than two decades of experience working in a variety of roles covering commercial, strategy, business development and mergers and acquisitions for global corporations in agriculture, food, energy and materials fields. Prior to joining us he was Assistant Vice President for Food Ingredients and Bio-industrial Enterprise at Cargill. At Cargill, he was responsible for revenues of over $1 billion, leading the commercial enterprise team to triple its earnings from bio-based products and managing relationships with large institutional customers. His prior roles at Cargill included Business Development Director for Starches and Sweeteners North America as well as serving as an investment team member with the Emerging Business Accelerator, a group structured along corporate venture capital groups, to invest in white space opportunities for Cargill; he also worked in the Corporate Strategy & Development Group. Mr. Sahoo has also served on the boards of both Calysta Inc. and Rivertop Renewables as a Cargill representative. He was responsible for leading Cargill’s equity investments in the industrial biotechnology space including co-investment in real assets with institutional financial investors to build a $600 million commercial-scale aquaculture nutrition plant. He also serves on Industry Advisory Board of Larta Institute which assists the USDA, NIH and NSF with the commercialization assistance program.
Glenn Bowers

Glenn Bowers自2015年12月起担任育种副总裁。他负责所有作物的育种、田间试验和种子生产。鲍尔斯博士拥有植物病理学的硕士和博士学位,专注于抗药性的育种和遗传学。他花了17年时间在德克萨斯农工大学管理大豆育种项目,之后又在普渡大学管理了一年。随后,他在先正达工作了16年,先是管理一个大豆育种项目,然后担任大豆育种全球主管。他在阿根廷和巴西以及北美拥有丰富的经验。他也是PMP的认证项目经理。鲍尔斯博士通过与营销和供应链的有效合作,在全球和美国提供产品方面拥有丰富的经验。他擅长创建,开发和管理多样化且全球分散的团队。


Glenn Bowers has served as our Vice President of Breeding since December 2015. He is responsible for breeding, field trialing and seed production for all crops. Dr. Bowers has M.S. and Ph.D. degrees in Plant Pathology with a focus on breeding and genetics of resistance. He spent 17 years managing a soybean breeding program with Texas A&M University, followed by a year doing the same at Purdue University. He then spent 16 years with Syngenta, first managing a soybean breeding program and then as global head of soybean breeding. He has extensive experience in Argentina and Brazil, in addition to North America. He is also a certified project manager PMP. Dr. Bowers has extensive experience in delivering products, both global and stateside, through effective collaboration with marketing and supply chain. He is skilled in creating, developing, and managing diverse and globally dispersed teams.
Glenn Bowers自2015年12月起担任育种副总裁。他负责所有作物的育种、田间试验和种子生产。鲍尔斯博士拥有植物病理学的硕士和博士学位,专注于抗药性的育种和遗传学。他花了17年时间在德克萨斯农工大学管理大豆育种项目,之后又在普渡大学管理了一年。随后,他在先正达工作了16年,先是管理一个大豆育种项目,然后担任大豆育种全球主管。他在阿根廷和巴西以及北美拥有丰富的经验。他也是PMP的认证项目经理。鲍尔斯博士通过与营销和供应链的有效合作,在全球和美国提供产品方面拥有丰富的经验。他擅长创建,开发和管理多样化且全球分散的团队。
Glenn Bowers has served as our Vice President of Breeding since December 2015. He is responsible for breeding, field trialing and seed production for all crops. Dr. Bowers has M.S. and Ph.D. degrees in Plant Pathology with a focus on breeding and genetics of resistance. He spent 17 years managing a soybean breeding program with Texas A&M University, followed by a year doing the same at Purdue University. He then spent 16 years with Syngenta, first managing a soybean breeding program and then as global head of soybean breeding. He has extensive experience in Argentina and Brazil, in addition to North America. He is also a certified project manager PMP. Dr. Bowers has extensive experience in delivering products, both global and stateside, through effective collaboration with marketing and supply chain. He is skilled in creating, developing, and managing diverse and globally dispersed teams.
Michel Arbadji

Michel Arbadji自2015年7月起担任我们的业务发展总监。Arbadji先生管理外部供应链运营。Arbadji先生在法国巴黎的巴黎格里尼翁国家农艺研究所获得农业工程学位和经济学和农业机械硕士学位。加入我们之前,他曾领导签名控制系统的欧洲和中东业务,建立和管理分销网络、欧盟市场营销与销售。在此期间,他担任约翰迪尔(John Deere)欧洲高尔夫灌溉部新业务开发的项目经理,拥有440多个客户。他的职业生涯始于任职The Toro Company EMEA公司,在那里他曾担任多种职务,涉及业务开发、销售与市场营销。在他27年的职业生涯中,他成功地建立了从研发到大型分销渠道建立的几个开拓性业务。他还参加了国际市场上的几次产品发布会。在Cellectis的职业生涯中,他曾于2013年至2015年担任Sceil the Stem Cells Project的首席执行官。他擅长谈判、沟通和执行复杂的任务。


Michel Arbadji has served as our Director of Business Development since July 2015. Mr. Arbadji manages the external supply chain operations. Mr. Arbadji received his degree in Agriculture Engineering and M.A. in Economics and Agriculture Machinery from the Institut National Agronomique Paris Grignon in Paris, France. Prior to joining us, he headed the European and Middle East Operation for Signature Control Systems, build and managed the distribution network, EU marketing and sales. During that period he managed as project manager the new business development of the golf Irrigation division in Europe at John Deere with over 440 accounts. Mr. Arbadji started his career at the Toro Company EMEA, where he held several positions in business development, sales and marketing. Over his 27 years career he successfully built several pioneering businesses from R&D to large scale distribution channels set up. He participated as well in several product launches on the international market. In his career at Cellectis he served as CEO for Sceil the stem cells project 2013 - 2015. He is skilled in negotiation, communication and in delivering complex tasks.
Michel Arbadji自2015年7月起担任我们的业务发展总监。Arbadji先生管理外部供应链运营。Arbadji先生在法国巴黎的巴黎格里尼翁国家农艺研究所获得农业工程学位和经济学和农业机械硕士学位。加入我们之前,他曾领导签名控制系统的欧洲和中东业务,建立和管理分销网络、欧盟市场营销与销售。在此期间,他担任约翰迪尔(John Deere)欧洲高尔夫灌溉部新业务开发的项目经理,拥有440多个客户。他的职业生涯始于任职The Toro Company EMEA公司,在那里他曾担任多种职务,涉及业务开发、销售与市场营销。在他27年的职业生涯中,他成功地建立了从研发到大型分销渠道建立的几个开拓性业务。他还参加了国际市场上的几次产品发布会。在Cellectis的职业生涯中,他曾于2013年至2015年担任Sceil the Stem Cells Project的首席执行官。他擅长谈判、沟通和执行复杂的任务。
Michel Arbadji has served as our Director of Business Development since July 2015. Mr. Arbadji manages the external supply chain operations. Mr. Arbadji received his degree in Agriculture Engineering and M.A. in Economics and Agriculture Machinery from the Institut National Agronomique Paris Grignon in Paris, France. Prior to joining us, he headed the European and Middle East Operation for Signature Control Systems, build and managed the distribution network, EU marketing and sales. During that period he managed as project manager the new business development of the golf Irrigation division in Europe at John Deere with over 440 accounts. Mr. Arbadji started his career at the Toro Company EMEA, where he held several positions in business development, sales and marketing. Over his 27 years career he successfully built several pioneering businesses from R&D to large scale distribution channels set up. He participated as well in several product launches on the international market. In his career at Cellectis he served as CEO for Sceil the stem cells project 2013 - 2015. He is skilled in negotiation, communication and in delivering complex tasks.